Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Log In

Novel Uveitis Treatment Strategies: A Discussion with Drs. Wykoff and Yeh


This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1.0

This webinar focuses on the risk of vision loss associated with each type of uveitis, and reviews the safety and efficacy of different treatment modalities for noninfectious posterior uveitis, including corticosteroids, sustained-release implants, immunomodulatory agents, and biologics. Potential advantages of steroid administration to the suprachoroidal space will also be discussed.

Expiration Date: Thursday, January 16, 2020
Release Date: January 2019

Learning Objectives

Upon completion of this activity, the participant should be able to:
• Describe the risk of vision loss associated with each type of uveitis.
• Evaluate the safety and efficacy of different treatment modalities for noninfectious posterior uveitis, including corticosteroids, sustained-release implants, immunomodulatory/immunosuppressive agents, and biologics.
• Discuss the potential advantages of steroid administration to the suprachoroidal space.

Accreditation and Designation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

Steven Yeh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Clearside Biomedical, Inc.; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceuticals.

Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Inc.; Allergan, plc; Bayer; Clearside Biomedical, Inc.; DORC International; EyePoint/pSivida; Genentech, Inc.; Notal Vision; Novartis; ONL Therapeutics; Regeneron Pharmaceuticals, Inc.; and Roche. Speaker’s Bureau: Regeneron Pharmaceuticals, Inc. Grant/Research Support: Adverum; Aerpio; Alcon; Aldeyra; Allegro Ophthalmics; Allergan, Inc.; Apellis Pharmaceuticals; Clearside Biomedical, Inc.; EyePoint/pSivida; Genentech, Inc.; Iconic Therapeutics; Johns Hopkins University; NEI; Novartis; OHR; Ophthotech Corporation; Regeneron Pharmaceuticals, Inc.; Roche; Santen Pharmaceuticals; Taiwan Liposome Company; and Tyrogenex.

Editorial Support Disclosure
Susan Gallagher-Pecha, director of client services and project management, Evolve Medical Education LLC, and Erin Fletcher, MIT, Evolve Medical Education LLC, have no real or apparent conflicts of interest to report. Jaya Kumar, MD, peer reviewer has no conflict of interest to report.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Clearside Biomedical, Inc.

Video Resources